Journal
CLINICAL AND VACCINE IMMUNOLOGY
Volume 22, Issue 2, Pages 221-228Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/CVI.00516-14
Keywords
-
Categories
Funding
- NIH [PO1 AI057788, P30DK5638, P30 CA125123]
- graduate fellowship (Agriculture and Food Research Initiative competitive grant from the USDA National Institute of Food and Agriculture) [2011-68003-30395]
Ask authors/readers for more resources
The human noroviruses (NoVs) are genetically diverse, rapidly evolving RNA viruses and are the major cause of epidemic gastroenteritis of humans. Serum antibodies that block the interaction of NoVs and NoV viruslike particles (VLPs) with host attachment factors are considered surrogate neutralizing antibodies in the absence of cell culture and small-animal replication models for the human NoVs. A serological assay for NoV-blocking antibodies was used to assess the breadth of the heterotypic antibody response in the context of an experimental challenge study with a human NoV. Heterotypic histo-blood group antigen (HBGA)-blocking activity against GI.4, GI.7, and GII.4 NoVs increased significantly in the serum of individuals (n = 18) infected with Norwalk virus (GI.1). Although the fold increases and peak titers of heterotypic antibody were more modest than titers of antibody reactive with the challenge antigen, Norwalk virus infection elicited a serological rise even against the novel Sydney variant of GII.4 NoVs. These observations indicate that the development of a broadly cross-protective NoV vaccine containing a limited number of genotypes may be possible.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available